408 related articles for article (PubMed ID: 6424339)
41. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.
Hanebutt FL; Rolf N; Loesel A; Kuhlisch E; Siegert G; Knoefler R
Haemophilia; 2008 May; 14(3):524-30. PubMed ID: 18284449
[TBL] [Abstract][Full Text] [Related]
42. Successful surgical haemostasis in patients with von Willebrand disease with Koate DVI.
Viswabandya A; Mathews V; George B; Nair SC; Baidya S; Mammen JJ; Chandy M; Srivastava A
Haemophilia; 2008 Jul; 14(4):763-7. PubMed ID: 18445014
[TBL] [Abstract][Full Text] [Related]
43. The factor VIII/von Willebrand factor complex: basic and clinical issues.
Federici AB
Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
[TBL] [Abstract][Full Text] [Related]
44. Concentrated DDAVP: further improvement in the management of mild factor VIII deficiencies.
Ghirardini A; Mariani G; Iacopino G; Tirindelli MC; Solinas S; Moretti T
Thromb Haemost; 1987 Oct; 58(3):896-8. PubMed ID: 3124287
[TBL] [Abstract][Full Text] [Related]
45. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R
Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
[TBL] [Abstract][Full Text] [Related]
46. Desmopressin (DDAVP) for treatment of disorders of hemostasis.
Mannucci PM
Prog Hemost Thromb; 1986; 8():19-45. PubMed ID: 3104987
[TBL] [Abstract][Full Text] [Related]
47. [Von Willebrand disease: characteristics and response to desmopressin. Study of 103 cases].
César JM; Avello AG; Vecino A; Cerveró C; Laraña JG; Fuertes IF; Villarrubia J; López J; de Oteyza JP; Velasco JL; Cantalapiedra A; Herrera P; Herrero S; Navarro JL
Med Clin (Barc); 1998 Nov; 111(16):601-3. PubMed ID: 9881332
[TBL] [Abstract][Full Text] [Related]
48. Response of patients with bleeding disorder to DDAVP administration.
Chuansumrit A; Hathirat P; Pintadit P; Isarangkura P
Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():174-9. PubMed ID: 7886567
[TBL] [Abstract][Full Text] [Related]
49. Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion.
Frank RD; Kunz D; Wirtz DC
Am J Hematol; 2002 May; 70(1):64-71. PubMed ID: 11994985
[TBL] [Abstract][Full Text] [Related]
50. Regulated release of VWF and FVIII and the biologic implications.
Haberichter SL; Shi Q; Montgomery RR
Pediatr Blood Cancer; 2006 May; 46(5):547-53. PubMed ID: 16470522
[TBL] [Abstract][Full Text] [Related]
51. Multiple congenital coagulopathies co-expressed with Von Willebrand's disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature.
Asatiani E; Kessler CM;
Haemophilia; 2007 Nov; 13(6):685-96. PubMed ID: 17973844
[TBL] [Abstract][Full Text] [Related]
52. Mild forms of von Willebrand disease: diagnosis and management.
Federici AB
Curr Hematol Rep; 2003 Sep; 2(5):373-80. PubMed ID: 12932308
[TBL] [Abstract][Full Text] [Related]
53. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
54. [A case of von Willebrand's disease--successful application of 1-deamino-8-D-arginine vasopressin (DDAVP) to ovarian bleeding].
Shiraishi K; Ebata H; Sato K; Tanaka M; Nouno R; Mashiko N; Yamaguchi G; Kubo Y; Tanikawa K; Ide K
Rinsho Ketsueki; 1983 Dec; 24(12):1674-9. PubMed ID: 6608600
[No Abstract] [Full Text] [Related]
55. [DDAVP: alternative therapy in moderate pathology of Factor VIII/von Willebrand].
Vicente V; Alberca I; Moraleda JM; López Borrasca A
Sangre (Barc); 1983; 28(4):531-2. PubMed ID: 6606856
[No Abstract] [Full Text] [Related]
56. [Treatment of hemophilia A and von Willebrand's disease with 1-deamino-8-D-arginine vasopressin (DDAVP). Hemophilia and DDAVP].
Ingerslev J; Christiansen SE; Kristensen T; Wallevik K; Bernvil SS
Ugeskr Laeger; 1985 Nov; 147(45):3592-4. PubMed ID: 3907076
[No Abstract] [Full Text] [Related]
57. The effects of desmopressin on plasma factor VIII/von Willebrand factor activity in dogs with von Willebrand's disease.
Johnstone IB; Crane S
Can J Vet Res; 1987 Apr; 51(2):189-93. PubMed ID: 3111674
[TBL] [Abstract][Full Text] [Related]
58. [Subcutaneous injection of desmopressin (DDAVP) for increasing factor VIII and von Willebrand factor in plasmapheresis].
Köhler M; Kotitschke R; Braun B; Hellstern P; Mörsdorf S; Pindur G; Heiden M; Wenzel E
Beitr Infusionsther; 1990; 26():136-41. PubMed ID: 1703813
[TBL] [Abstract][Full Text] [Related]
59. Management of inherited von Willebrand disease in 2006.
Federici AB
Semin Thromb Hemost; 2006 Sep; 32(6):616-20. PubMed ID: 16977571
[TBL] [Abstract][Full Text] [Related]
60. Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results.
Bello IF; Yuste VJ; Molina MQ; Navarro FH
Haemophilia; 2007 Dec; 13 Suppl 5():25-32. PubMed ID: 18078394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
